

**REMARKS**

The Notice indicated that the amendment was non-compliant with the format required pursuant to 37 C.F.R. 1.121, as amended September 8, 2000 in that the amendment did not include a marked up version of the amended claims as required by 37 C.F.R. 1.121(c)(1)(ii).

Attached hereto is a marked-up version of the changes made to the claims by the amendment filed on June 19, 2001. The attached pages are captioned, "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

**CONCLUSION**


Applicants believe that the pending claims, as amended are in condition for allowance. Consequently, the Applicants respectfully request that this pending claims in this application be granted favorable consideration and this application passed to issuance without further delay.

If the Examiner believes that an interview would expedite the prosecution of this application, the Applicants' attorney would welcome the opportunity to discuss this application further with the Examiner by telephone to resolve any outstanding issues.

Canji, Inc.  
3525 John Hopkins Court  
San Diego, CA 92121  
Telephone: 858-646-5955  
Facsimile: 858-452-4945

Dated: October 25, 2001

Respectfully submitted,

  
Richard B. Murphy  
Attorney for Applicants  
Registration No. 35,296

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Claims:**

Claim 5 has been amended as follows:

5. (Amended) A method of increasing the infectivity of a cell to a viral vector by treatment of the cell with a micro-calpain inhibitor.

Claim 7 has been amended as follows:

7. (Amended) The method of claim 6 wherein the micro-calpain inhibitor is calpain inhibitor 1.

Claim 17 has been cancelled.

The following new claims 21-36 have been added:

21. (New) The method of claim 6 wherein said adenoviral vector is replication deficient.

22. (New) The method of claim 21 wherein said replication deficient adenoviral vector encodes a therapeutic transgene.

23. (New) The method of claim 22 where said transgene is selected from the group consisting of cytostatic genes and pro-apoptotic genes.

24. (New) The method of claim 23 wherein the gene is a cytostatic gene.

25. (New) The method of claim 24 wherein the gene is the p21 gene.

26. (New) The method of claim 23 wherein the gene is a pro-apoptotic gene.

27. (New) The method of claim 26 wherein the gene is p53.

28. (New) The method of claim 5 wherein the vector is replication competent.

29. (New) The method of claim 28 wherein the replication competent vector is a conditionally replicating viral vector.

30. (New) The method of claim 29 wherein the conditionally replicating viral vector further comprises an expression cassette which expresses a pro-apoptotic gene.

31. (New) The method of claim 30 wherein the pro-apoptotic gene is the E3-11.6K gene.

32. (New) The method of claim 5 wherein the method is practiced *in vitro*.

33. (New) The method of claim 32 wherein the viral vector is a replication deficient adenoviral vector and the cell is a producer cell capable of complementing the deleted functions of the replication deficient adenoviral vector.

C)

34. (New) The method of claim 33 wherein the replication deficient adenoviral vector lacks a functional E1 region and the producer cell is a 293 cell.
35. (New) The method of claim 32 wherein said *in vitro* practice of the method is in a process to purge tumor cells from a stem cell product by exposing said stem cell product to a calpain inhibitor prior to the administration of a viral vector.
36. (New) The method of claim 35 wherein said viral vector is an adenoviral vector that encodes and expresses the p53 tumor suppressor gene.

---